BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 23755721)

  • 1. Pharmacokinetics of 3'-O-retinoyl-5-fluoro-2'-deoxyuridine (RFUdR), a dual acting mutually masking prodrug, and its metabolites in tumor bearing mice.
    Xia Z; Knaus EE; Wiebe LI
    Curr Drug Deliv; 2013 Oct; 10(5):557-63. PubMed ID: 23755721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of butanoate, retinoate, and bis(2,2,2-trichloroethyl)phosphate derivatives of 5-fluoro-2'-deoxyuridine and 2',5-difluoro-2'-deoxyuridine as potential dual action anticancer prodrugs.
    Xia Z; Wiebe LI; Miller GG; Knaus EE
    Arch Pharm (Weinheim); 1999 Aug; 332(8):286-94. PubMed ID: 10489539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo distribution and antitumour activity of liposomal 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine.
    Van Borssum Waalkes M; Fichtner I; Dontje B; Lemm M; Becker M; Arndt D; Scherphof GL
    J Microencapsul; 1992; 9(3):335-46. PubMed ID: 1403484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of organ-specific immunoliposomes for delivery of 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung-metastasis model.
    Mori A; Kennel SJ; van Borssum Waalkes M; Scherphof GL; Huang L
    Cancer Chemother Pharmacol; 1995; 35(6):447-56. PubMed ID: 7882453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antitumour effect of lipophilic derivatives of 5-fluoro-2'-deoxyuridine incorporated into liposomes.
    Supersaxo A; Rubas W; Hartmann HR; Schott H; Hengartner H; Schwendener RA
    J Microencapsul; 1988; 5(1):1-11. PubMed ID: 2974073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity of liposomal 3'-5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in mice.
    van Borssum Waalkes M; Goris H; Dontje BH; Schwendener RA; Scherphof G; Nijhof W
    Anticancer Drug Des; 1998 Jun; 13(4):291-305. PubMed ID: 9627669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats.
    Stecklair KP; Hamburger DR; Egorin MJ; Parise RA; Covey JM; Eiseman JL
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):375-82. PubMed ID: 11761455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.
    de Jong J; Geijssen GJ; Munniksma CN; Vermorken JB; van der Vijgh WJ
    J Clin Oncol; 1992 Dec; 10(12):1897-906. PubMed ID: 1453205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells.
    Koning GA; Morselt HW; Velinova MJ; Donga J; Gorter A; Allen TM; Zalipsky S; Kamps JA; Scherphof GL
    Biochim Biophys Acta; 1999 Aug; 1420(1-2):153-67. PubMed ID: 10446299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled release of 5-fluoro-2'-deoxyuridine by the combination of prodrug and polymer matrix.
    Endoh H; Kawaguchi T; Seki T; Hasegawa T; Juni K
    Chem Pharm Bull (Tokyo); 1991 Feb; 39(2):458-64. PubMed ID: 1829027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5'-[2-(2-Nitrophenyl)-2-methylpropionyl]-2'-deoxy-5-fluorouridine as a potential bioreductively activated prodrug of FUDR: synthesis, stability and reductive activation.
    Hu L; Liu B; Hacking DR
    Bioorg Med Chem Lett; 2000 Apr; 10(8):797-800. PubMed ID: 10782689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits.
    Groll AH; Mickiene D; Petraitis V; Petraitiene R; Kelaher A; Sarafandi A; Wuerthwein G; Bacher J; Walsh TJ
    J Antimicrob Chemother; 2005 Nov; 56(5):899-907. PubMed ID: 16172108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposome-incorporated 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine as a slow-release anti-tumor drug depot in rat liver macrophages.
    Van Borssum Waalkes M; Scherphof GL
    Sel Cancer Ther; 1990; 6(1):15-22. PubMed ID: 2140463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and bioavailability of 5-ethyl-2'-deoxyuridine and its novel (5R,6R)-5-bromo-6-ethoxy-5,6-dihydro prodrugs in mice.
    Cheraghali AM; Kumar R; Knaus EE; Wiebe LI
    Drug Metab Dispos; 1995 Feb; 23(2):223-6. PubMed ID: 7736915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and tissue distribution of (+/-)-3'-azido-2',3'-dideoxy-5'-O-(2-bromomyristoyl)thymidine, a prodrug of 3'-azido-2',3'-dideoxythymidine (AZT) in mice.
    Parang K; Wiebe LI; Knaus EE
    J Pharm Pharmacol; 1998 Sep; 50(9):989-96. PubMed ID: 9811159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.
    Egorin MJ; Lagattuta TF; Hamburger DR; Covey JM; White KD; Musser SM; Eiseman JL
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):7-19. PubMed ID: 11855755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro stability and cytostatic activity of liposomal formulations of 5-fluoro-2'-deoxyuridine and its diacylated derivatives.
    van Borssum Waalkes M; van Galen M; Morselt H; Sternberg B; Scherphof GL
    Biochim Biophys Acta; 1993 May; 1148(1):161-72. PubMed ID: 8499464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effect and tumor level of 5-fluoro-2'-deoxyuridylate following oral administration of tetradecyl 2'-deoxy-5-fluoro-5'-uridylate.
    Nakajima Y; Iigo M; Hoshi A
    Anticancer Drugs; 1992 Jun; 3(3):289-92. PubMed ID: 1525410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bifunctional and Unusual Amino Acid β- or γ-Ester Prodrugs of Nucleoside Analogues for Improved Affinity to ATB
    Sun Y; Ke Y; Li C; Wang J; Tu L; Hu L; Jin Y; Chen H; Gong J; Yu Z
    J Med Chem; 2020 Oct; 63(19):10816-10828. PubMed ID: 32882127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.